Literature DB >> 20414792

Conformational analysis of piperazine and piperidine analogs of GBR 12909: stochastic approach to evaluating the effects of force fields and solvent.

Deepangi Pandit1, William Roosma, Milind Misra, Kathleen M Gilbert, William J Skawinski, Carol A Venanzi.   

Abstract

Analogs of the flexible dopamine reuptake inhibitor, GBR 12909 (1), may have potential utility in the treatment of cocaine abuse. As a first step in the 3D-QSAR modeling of the dopamine transporter (DAT)/serotonin transporter (SERT) selectivity of these compounds, we carried out conformational analyses of two analogs of 1: a piperazine (2) and a related piperidine (3). Ensembles of conformers consisting of local minima on the potential energy surface of the molecule were generated in the vacuum phase and in implicit solvent by random search conformational analysis using the Tripos and MMFF94 force fields. Some differences were noted in the conformer populations due to differences in the treatment of the tertiary amine nitrogen and ether oxygen atom types by the force fields. The force fields also differed in their descriptions of internal rotation around the C(sp³)-O(sp³) bond proximal to the bisphenyl moiety. Molecular orbital calculations at the HF/6-31G(d) and B3LYP/6-31G(d) levels of C-O internal rotation in model compound (5), designed to model the effect of the proximity of the bisphenyl group on C-O internal rotation, showed a broad region of low energy between -60° to 60° with minima at both -60° and 30° and a low rotational barrier at 0°, in closer agreement with the MMFF94 results than the Tripos results. Molecular mechanics calculations on model compound (6) showed that the MMFF94 force field was much more sensitive than the Tripos force field to the effects of the bisphenyl moiety on C-O internal rotation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20414792     DOI: 10.1007/s00894-010-0712-x

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  18 in total

Review 1.  Dopamine transporter ligands: recent developments and therapeutic potential.

Authors:  Scott P Runyon; F Ivy Carroll
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

2.  Feature extraction using molecular planes for fuzzy relational clustering of a flexible dopamine reuptake inhibitor.

Authors:  Amit Banerjee; Milind Misra; Deepa Pai; Liang-Yu Shih; Rohan Woodley; Xiang-Jun Lu; A R Srinivasan; Wilma K Olson; Rajesh N Davé; Carol A Venanzi
Journal:  J Chem Inf Model       Date:  2007-10-30       Impact factor: 4.956

3.  Modeling of the pH dependence of the binding of WIN 35,428 to the dopamine transporter in rat striatal membranes: is the bioactive form positively charged or neutral?

Authors:  C Xu; M E Reith
Journal:  J Pharmacol Exp Ther       Date:  1996-09       Impact factor: 4.030

4.  Novel feature extraction technique for fuzzy relational clustering of a flexible dopamine reuptake inhibitor.

Authors:  Milind Misra; Amit Banerjee; Rajesh N Davé; Carol A Venanzi
Journal:  J Chem Inf Model       Date:  2005 May-Jun       Impact factor: 4.956

5.  Conformational analysis of methylphenidate: comparison of molecular orbital and molecular mechanics methods.

Authors:  Kathleen M Gilbert; William J Skawinski; Milind Misra; Kristina A Paris; Neelam H Naik; Ronald A Buono; Howard M Deutsch; Carol A Venanzi
Journal:  J Comput Aided Mol Des       Date:  2004-11       Impact factor: 3.686

6.  Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors.

Authors:  D Matecka; D Lewis; R B Rothman; C M Dersch; F H Wojnicki; J R Glowa; A C DeVries; A Pert; K C Rice
Journal:  J Med Chem       Date:  1997-02-28       Impact factor: 7.446

7.  GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND).

Authors:  Paolo Benedetti; Raimund Mannhold; Gabriele Cruciani; Manuel Pastor
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

8.  Which form of dopamine is the substrate for the human dopamine transporter: the cationic or the uncharged species?

Authors:  J L Berfield; L C Wang; M E Reith
Journal:  J Biol Chem       Date:  1999-02-19       Impact factor: 5.157

9.  Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate.

Authors:  Deog-Il Kim; Howard M Deutsch; Xiaocong Ye; Margaret M Schweri
Journal:  J Med Chem       Date:  2007-05-10       Impact factor: 7.446

10.  Structure-activity relationship studies of novel 4-[2-[bis(4-fluorophenyl)methoxy]ethyl]-1-(3-phenylpropyl)piperidine analogs: synthesis and biological evaluation at the dopamine and serotonin transporter sites.

Authors:  A K Dutta; C Xu; M E Reith
Journal:  J Med Chem       Date:  1996-02-02       Impact factor: 7.446

View more
  3 in total

1.  Singular value decomposition analysis of the torsional angles of dopamine reuptake inhibitor GBR 12909 analogs: effect of force field and charges.

Authors:  Deepangi Pandit; Anna Fiorentino; Supreet Bindra; Carol A Venanzi
Journal:  J Mol Model       Date:  2010-09-14       Impact factor: 1.810

2.  Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.

Authors:  Horrick Sharma; Soumava Santra; Joy Debnath; Tamara Antonio; Maarten Reith; Aloke Dutta
Journal:  Bioorg Med Chem       Date:  2013-11-19       Impact factor: 3.641

3.  Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): effects on binding affinity and selectivity for sigma receptors and monoamine transporters.

Authors:  Rong Xu; Sarah A Lord; Ryan M Peterson; Emily A Fergason-Cantrell; John R Lever; Susan Z Lever
Journal:  Bioorg Med Chem       Date:  2014-11-11       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.